Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-Adhoc: STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025
EQS-Adhoc: STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025
EQS-Adhoc: STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025
EQS-News: Evotec SE to announce results for the first nine months 2025 on 05 November 2025
EQS-News: Evotec SE to announce results for the first nine months 2025 on 05 November 2025
EQS-News: Evotec SE to announce results for the first nine months 2025 on 05 November 2025
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with strong demand, noticeable net sales growth and very good earnings performance in the first nine months of 2025
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with strong demand, noticeable net sales growth and very good earnings performance in the first nine months of 2025
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with strong demand, noticeable net sales growth and very good earnings performance in the first nine months of 2025
EQS-News: Gerresheimer: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen 
EQS-News: Gerresheimer: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen 
EQS-News: Gerresheimer: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen 
EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen
EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen
EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen
3 Healthcare Stocks to Buy Hand Over Fist in October: https://g.foolcdn.com/editorial/images/839533/23_11_13-a-scientist-working-with-a-flask-and-beaker-_gettyimages-1413606015-1201x633-65d4be6.jpg
3 Healthcare Stocks to Buy Hand Over Fist in October

If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each

EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
EQS-Adhoc: Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
EQS-Adhoc: Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
EQS-Adhoc: Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
2 Beaten-Down Stocks to Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/837781/physician-giving-medicine-to-elderly-patient.jpg
2 Beaten-Down Stocks to Buy and Hold for the Next Decade

The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means

EQS-News: Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
EQS-News: Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?: https://g.foolcdn.com/editorial/images/830019/doctor-and-patient-talking.jpg
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a

EQS-News: Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
EQS-News: Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
EQS-News: Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
EQS-News: Biotest’s Yimmugo® launches in the United States
EQS-News: Biotest’s Yimmugo® launches in the United States
EQS-News: Biotest’s Yimmugo® launches in the United States
EQS-News: Gerresheimer: Business performance and slower market growth require guidance adjustment
EQS-News: Gerresheimer: Business performance and slower market growth require guidance adjustment
EQS-News: Gerresheimer: Business performance and slower market growth require guidance adjustment
EQS-Adhoc: Gerresheimer AG: Business performance and slower market growth require adjustment of guidance for 2025
EQS-Adhoc: Gerresheimer AG: Business performance and slower market growth require adjustment of guidance for 2025
EQS-Adhoc: Gerresheimer AG: Business performance and slower market growth require adjustment of guidance for 2025
EQS-News: Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials
EQS-News: Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials
EQS-News: Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials
EQS-News: Gerresheimer comments on the audit by German BaFin
EQS-News: Gerresheimer comments on the audit by German BaFin
EQS-News: Gerresheimer comments on the audit by German BaFin
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
EQS-News: STRATEC ENLARGES ITS BOARD OF MANAGEMENT 
EQS-News: STRATEC ENLARGES ITS BOARD OF MANAGEMENT 
EQS-News: STRATEC ENLARGES ITS BOARD OF MANAGEMENT 
EQS-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2025
EQS-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2025
EQS-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2025
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks

If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but